Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab in advanced solid tumors
NCT03352531Phase 1Completed
- Sponsor
- Akeso, Inc.
- Start
- Jan 2018
- Primary completion
- Nov 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of penpulimab in solid tumor (advanced stage), sponsored by Akeso, Inc. Primary endpoints: Number of participants with adverse events (AEs) and Number of participants with a Dose Limiting Toxicity (DLT) at 4 weeks. Started Jan 2018; status: completed.
02
Drugs
penpulimab
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03352531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03352531.